AtheroGenics, Inc. a pharmaceutical company focused on the treatment of chronic inflammatory diseases today announced that early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period has been granted for its exclusive licensing agreement with AstraZeneca for the worldwide development and commercialization of AGI-1067, AtheroGenics' Phase III compound for the treatment of atherosclerosis. The expiration of the waiting period triggers the $50 million upfront payment to AtheroGenics by AstraZeneca and allows the two companies to actively begin collaboration for the clinical development and commercialization of AGI-1067.
CNW Group